Latest & greatest articles for copd

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on copd or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on copd and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for copd

101. Discriminative Accuracy of FEV1:FVC Thresholds for COPD-Related Hospitalization and Mortality. Full Text available with Trip Pro

Discriminative Accuracy of FEV1:FVC Thresholds for COPD-Related Hospitalization and Mortality. According to numerous current guidelines, the diagnosis of chronic obstructive pulmonary disease (COPD) requires a ratio of the forced expiratory volume in the first second to the forced vital capacity (FEV1:FVC) of less than 0.70, yet this fixed threshold is based on expert opinion and remains controversial.To determine the discriminative accuracy of various FEV1:FVC fixed thresholds for predicting (...) COPD-related hospitalization and mortality.The National Heart, Lung, and Blood Institute (NHLBI) Pooled Cohorts Study harmonized and pooled data from 4 US general population-based cohorts (Atherosclerosis Risk in Communities Study; Cardiovascular Health Study; Health, Aging, and Body Composition Study; and Multi-Ethnic Study of Atherosclerosis). Participants aged 45 to 102 years were enrolled from 1987 to 2000 and received follow-up longitudinally through 2016.Presence of airflow obstruction, which

2019 JAMA

102. Quantitative CT parameters correlate with lung function in chronic obstructive pulmonary disease: a systematic review and meta-analysis Full Text available with Trip Pro

version of this article is available . Abstract Background The aim of the study was to analyze the correlation between quantitative computed tomography (CT) parameters and airflow obstruction in patients with chronic obstruction pulmonary disease (COPD). Methods PubMed, Embase, Cochrane and Web of Knowledge were searched by two investigators from inception to 2018, using a combination of pertinent items to discover articles that investigated the relationship between CT measurements and lung function (...) Jing Wu Qinghai University Dong Han Shaanxi Provincial People's Hospital Wei Guan Corresponding Author ORCiD: https://orcid.org/0000-0002-1080-0509 DOI: License: This work is licensed under a CC BY 4.0 License. The most recent version of this article is available . Abstract Background The aim of the study was to analyze the correlation between quantitative computed tomography (CT) parameters and airflow obstruction in patients with chronic obstruction pulmonary disease (COPD). Methods PubMed

2019 Research Square

103. Meta-analysis of Gene Expression Microarray Datasets in Chronic Obstructive Pulmonary Disease Full Text available with Trip Pro

: Abstract Chronic obstructive pulmonary disease (COPD) was classified by the Centers for Disease Control and Prevention in 2014 as the 3 rd leading cause of death in the United States (US). The main cause of COPD is exposure to tobacco smoke and air pollutants. Problems associated with COPD include under-diagnosis of the disease and an increase in the number of smokers worldwide. The goal of our study is to identify disease variability in the gene expression profiles of COPD subjects compared (...) Meta-analysis of Gene Expression Microarray Datasets in Chronic Obstructive Pulmonary Disease Meta-analysis of Gene Expression Microarray Datasets in Chronic Obstructive Pulmonary Disease | bioRxiv Search for this keyword New Results Meta-analysis of Gene Expression Microarray Datasets in Chronic Obstructive Pulmonary Disease Lavida R. K. Rogers , Madison Verlinde , George I. Mias doi: https://doi.org/10.1101/671206 Lavida R. K. Rogers 1 Microbiology and Molecular Genetics, Michigan State

2019 Cold Spring Harbor Laboratory

104. CRP-guided antibiotic treatment in acute exacerbations of COPD in hospital admissions Full Text available with Trip Pro

CRP-guided antibiotic treatment in acute exacerbations of COPD in hospital admissions The role of antibiotics in acute exacerbations of chronic obstructive pulmonary disease (COPD) is controversial and a biomarker identifying patients who benefit from antibiotics is mandatory. We performed a randomised, controlled trial in patients with acute exacerbations of COPD, comparing C-reactive protein (CRP)-guided antibiotic treatment to patient reported symptoms in accordance with the Global (...) Initiative for Chronic Obstructive Lung Disease (GOLD) strategy, in order to show a reduction in antibiotic prescription.Patients hospitalised with acute exacerbations of COPD were randomised to receive antibiotics based either on the GOLD strategy or according to the CRP strategy (CRP ≥50 mg·L-1).In total, 101 patients were randomised to the CRP group and 119 to the GOLD group. Fewer patients in the CRP group were treated with antibiotics compared to the GOLD group (31.7% versus 46.2%, p=0.028; adjusted

2019 EvidenceUpdates

105. Effect of Dexamethasone on Nocturnal Oxygenation in Lowlanders With Chronic Obstructive Pulmonary Disease Traveling to 3100 Meters: A Randomized Clinical Trial Full Text available with Trip Pro

Effect of Dexamethasone on Nocturnal Oxygenation in Lowlanders With Chronic Obstructive Pulmonary Disease Traveling to 3100 Meters: A Randomized Clinical Trial During mountain travel, patients with chronic obstructive pulmonary disease (COPD) are at risk of experiencing severe hypoxemia, in particular, during sleep.To evaluate whether preventive dexamethasone treatment improves nocturnal oxygenation in lowlanders with COPD at 3100 m.A randomized, placebo-controlled, double-blind, parallel trial (...) was performed from May 1 to August 31, 2015, in 118 patients with COPD (forced expiratory volume in the first second of expiration [FEV1] >50% predicted, pulse oximetry at 760 m ≥92%) who were living at altitudes below 800 m. The study was conducted at a university hospital (760 m) and high-altitude clinic (3100 m) in Tuja-Ashu, Kyrgyz Republic. Patients underwent baseline evaluation at 760 m, were taken by bus to the clinic at 3100 m, and remained at the clinic for 2 days and nights. Participants were

2019 EvidenceUpdates

106. Care bundles to reduce re-admissions for patients with chronic obstructive pulmonary disease: a mixed-methods study Full Text available with Trip Pro

Care bundles to reduce re-admissions for patients with chronic obstructive pulmonary disease: a mixed-methods study Care bundles to reduce re-admissions for patients with chronic obstructive pulmonary disease: a mixed-methods study Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search above to find (...) the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> 1)"> {{metadata.Title}} {{metadata.Headline}} There was no evidence that care bundles reduced 28-day re-admission rates for chronic obstructive pulmonary disease and were challenging to implement. {{author}} {{($index , , , , , , , , , , , & . Katherine Morton 1 , Emily Sanderson 1, 2 , Padraig Dixon 1 , Anna King 1 , Sue Jenkins 3 , Stephanie J MacNeill 1, 2 , Alison Shaw 1 , Chris Metcalfe 1, 2 , Melanie Chalder 1 , William

2019 NIHR HTA programme

107. Bronchoscopic thermal vapour ablation for upper-lobe emphysema

and procedure The condition, current treatments and procedure The condition 2.1 Emphysema is a chronic lung disease that typically happens with chronic obstructive pulmonary disease. In emphysema, the walls of the air sacs (alveoli) in the lungs weaken and disintegrate. This leaves behind abnormally large air spaces that stay filled with air even when the patient breathes out. The most common symptoms of emphysema are shortness of breath, coughing, fatigue and weight loss. Recurrent illnesses (such as chest (...) . Lung volume reduction surgery is an option for patients who experience breathlessness, and whose pulmonary function tests and CT scans show severe disease and enlarged air spaces. Surgery can be done thoracoscopically or using an open approach. Endoscopic lung volume reduction techniques include implanting valves or coils. The aim is to reduce the morbidity and mortality associated with conventional surgery. The procedure 2.3 Bronchoscopic thermal vapour (steam) ablation for upper-lobe emphysema

2019 National Institute for Health and Clinical Excellence - Interventional Procedures

108. [Effectiveness of a brief educational intervention relating to the correct use of inhalers on the prevention of exacerbation in patients suffering from chronic obstructive pulmonary disease]. Full Text available with Trip Pro

[Effectiveness of a brief educational intervention relating to the correct use of inhalers on the prevention of exacerbation in patients suffering from chronic obstructive pulmonary disease]. To predict the effect of a brief educational intervention aimed at improving the inhaler technique on the reduction of exacerbations in patients with COPD over a year.A triple blind, randomised controlled clinical trial with parallel design.to be between 40-75 years, having been diagnosed with COPD (...) of exacerbations in each group was checked.social and demographic, study, dyspnoea level, body-mass index, tobacco use, FEV1, FEV1/FVC, COPD stage, BODEX index, number, type, and inhaler technique, number of previous exacerbations. Bayesian inference analysis was performed using logistic regression models.A total of 56 patients were assigned to de intervention group and 41 to the control one. There were 16 and 14 lost to follow-up, respectively. In the intervention group, 44.6% of the patients had

2019 Semergen Controlled trial quality: uncertain

109. Head-to-head oral prophylactic antibiotic therapy for chronic obstructive pulmonary disease. Full Text available with Trip Pro

Head-to-head oral prophylactic antibiotic therapy for chronic obstructive pulmonary disease. Chronic obstructive pulmonary disease (COPD; including chronic bronchitis and emphysema) is a chronic respiratory condition characterised by shortness of breath, cough and recurrent exacerbations. Long-term antibiotic use may reduce both bacterial load and inflammation in the airways. Studies have shown a reduction of exacerbations with antibiotics in comparison to placebo in people with COPD (...) ).Overall, we judged the evidence presented to be of very low-certainty, mainly due to imprecision, but we also had concerns about indirectness and methodological quality of the included studies. The primary outcome measures for this review included exacerbations, quality of life, drug resistance and serious adverse events.Macrolide + tetracycline versus macrolide There was no clear difference between treatments in improvement in quality of life as assessed by the Chronic Respiratory Questionnaire (CRQ

2019 Cochrane

110. Benralizumab for the Prevention of COPD Exacerbations. Full Text available with Trip Pro

Benralizumab for the Prevention of COPD Exacerbations. The efficacy and safety of benralizumab, an interleukin-5 receptor alpha-directed cytolytic monoclonal antibody, for the prevention of exacerbations in patients with moderate to very severe chronic obstructive pulmonary disease (COPD) are not known.In the GALATHEA and TERRANOVA trials, we enrolled patients with COPD (at a ratio of approximately 2:1 on the basis of eosinophil count [≥220 per cubic millimeter vs. <220 per cubic millimeter (...) ]) who had frequent exacerbations despite receiving guideline-based inhaled treatment. Patients were randomly assigned to receive benralizumab (30 or 100 mg in GALATHEA; 10, 30, or 100 mg in TERRANOVA) every 8 weeks (every 4 weeks for the first three doses) or placebo. The primary end point was the treatment effect of benralizumab, measured as the annualized COPD exacerbation rate ratio (benralizumab vs. placebo) at week 56 in patients with baseline blood eosinophil counts of 220 per cubic millimeter

2019 NEJM Controlled trial quality: predicted high

111. Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease. Full Text available with Trip Pro

Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease. Individuals with chronic bronchitis or chronic obstructive pulmonary disease (COPD) may suffer recurrent exacerbations with an increase in volume or purulence of sputum, or both. Personal and healthcare costs associated with exacerbations indicate that therapies that reduce the occurrence of exacerbations are likely to be useful. Mucolytics are oral medicines that are believed to increase (...) = 11; I² = 0%; moderate-certainty evidence).In participants with chronic bronchitis or COPD, we are moderately confident that treatment with mucolytics leads to a small reduction in the likelihood of having an acute exacerbation, in days of disability per month and possibly hospitalisations, but is not associated with an increase in adverse events. There appears to be limited impact on lung function or health-related quality of life. Results are too imprecise to be certain whether

2019 Cochrane

112. Effect of Aclidinium Bromide on Major Cardiovascular Events and Exacerbations in High-Risk Patients With Chronic Obstructive Pulmonary Disease: The ASCENT-COPD Randomized Clinical Trial. Full Text available with Trip Pro

Effect of Aclidinium Bromide on Major Cardiovascular Events and Exacerbations in High-Risk Patients With Chronic Obstructive Pulmonary Disease: The ASCENT-COPD Randomized Clinical Trial. There is concern that long-acting muscarinic antagonists increase cardiovascular morbidity or mortality in patients with chronic obstructive pulmonary disease (COPD).To determine the cardiovascular safety (noninferiority) and efficacy (superiority) of aclidinium bromide, 400 μg twice daily, in patients (...) with COPD and cardiovascular disease or risk factors.Multicenter, randomized, placebo-controlled, double-blind, parallel-design study conducted at 522 sites in North America. A total of 3630 patients with moderate to very severe COPD and either a history of cardiovascular disease or at least 2 atherothrombotic risk factors were randomized; follow-up occurred for up to 3 years until at least 122 major adverse cardiovascular events (MACE) occurred. The first patient was enrolled on October 16, 2013

2019 JAMA Controlled trial quality: predicted high

113. Reducing Chronic Obstructive Pulmonary Disease Hospital Readmissions: A Workshop Report Full Text available with Trip Pro

Respiratory Research Network. Outcomes of patients with chronic obstructive pulmonary disease diagnosed with or without pulmonary function testing . CMAJ 2017 ;189: E530 – E538 . , , 35 . Gershon AS , Thiruchelvam D , Chapman KR , Aaron SD , Stanbrook MB , Bourbeau J , et al .; Canadian Respiratory Research Network. Health services burden of undiagnosed and overdiagnosed COPD . Chest 2018 ;153: 1336 – 1346 . , , 36 . Wu H , Wise RA , Medinger AE . Do patients hospitalized with COPD have airflow (...) for Chronic Obstructive Lung Disease. GOLD 2017: Global Strategy for the Diagnosis, Management and Prevention of COPD. Final revised 2017 Nov 20 [accessed 2017 Mar 12]. Available from: . 46 . Feemster LC , Au DH . Penalizing hospitals for chronic obstructive pulmonary disease readmissions . Am J Respir Crit Care Med 2014 ;189: 634 – 639 . , , 47 . Sjoding MW , Cooke CR . Readmission penalties for chronic obstructive pulmonary disease will further stress hospitals caring for vulnerable patient populations

2019 American Thoracic Society

114. Dual bronchodilation with tiotropium/olodaterol further reduces activity-related breathlessness versus tiotropium alone in COPD Full Text available with Trip Pro

Dual bronchodilation with tiotropium/olodaterol further reduces activity-related breathlessness versus tiotropium alone in COPD The 3-min constant speed shuttle test (CSST) was used to examine the effect of tiotropium/olodaterol compared with tiotropium at reducing activity-related breathlessness in patients with chronic obstructive pulmonary disease (COPD).This was a randomised, double-blind, two-period crossover study including COPD patients with moderate to severe pulmonary impairment, lung (...) -min CSST from baseline with both tiotropium (mean -0.968, 95% CI -1.238- -0.698; n=100) and tiotropium/olodaterol (mean -1.325, 95% CI -1.594- -1.056; n=101). The decrease in breathlessness was statistically significantly greater with tiotropium/olodaterol versus tiotropium (treatment difference -0.357, 95% CI -0.661- -0.053; p=0.0217).Tiotropium/olodaterol reduced activity-related breathlessness more than tiotropium in dyspnoeic patients with moderate to severe COPD exhibiting lung

2019 EvidenceUpdates

115. Diagnosis and Outpatient Management of Chronic Obstructive Pulmonary Disease: A Review. (Abstract)

to therapy. The diagnosis and treatment of COPD is rapidly changing, so understanding recent advances is important for the delivery of optimal patient care.Chronic obstructive pulmonary disease is characterized by incompletely reversible expiratory airflow limitation. Spirometry is the reference standard for diagnosing and assessing the severity of COPD. All patients should be counseled about and receive preventive measures such as smoking cessation and vaccination. Treatment should be guided (...) Diagnosis and Outpatient Management of Chronic Obstructive Pulmonary Disease: A Review. There are 30 million adults (12%) in the United States who have chronic obstructive pulmonary disease (COPD). Chronic obstructive pulmonary disease accounts for 3.2% of all physician office visits annually and is the fourth leading cause of death (126 000 deaths per year). Most patients are diagnosed by their primary care clinicians who must address the highly variable clinical features and responses

2019 JAMA

116. People with chronic obstructive pulmonary disease exacerbations prefer early discharge, then treatment at home. (Abstract)

People with chronic obstructive pulmonary disease exacerbations prefer early discharge, then treatment at home. The studyHome treatment of COPD exacerbation selected by DECAF score: a non-inferiority, randomised controlled trial and economic evaluationEchevarria C, Gray J, Hartley T, Miller J, Simpson AJ, Gibson GJ, Bourke SCPublished on 24 April 2018 Thorax 2018;73:713-22This project was funded by the National Institute for Health Research-Research for Patient Benefit Programme (project number (...) PB-PG-0213-30105).To read the full NIHR Signal, go to: https://discover.dc.nihr.ac.uk/content/signal-000691/hospital-at-home-treatment-for-copd-flare-ups.Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

2019 BMJ Controlled trial quality: uncertain

117. Cluster-randomised trial of a nurse-led advance care planning session in patients with COPD and their loved ones Full Text available with Trip Pro

Cluster-randomised trial of a nurse-led advance care planning session in patients with COPD and their loved ones Advance care planning (ACP) is uncommon in patients with chronic obstructive pulmonary disease (COPD).To assess whether a nurse-led ACP-intervention can improve quality of patient-physician end-of-life care communication in patients with COPD. Furthermore, the influence of an ACP-intervention on symptoms of anxiety and depression in patients and loved ones was studied. Finally (...) , quality of death and dying was assessed in patients who died during 2-year follow-up.A multicentre cluster randomised-controlled trial in patients with advanced COPD was performed. The intervention group received an 1.5 hours structured nurse-led ACP-session. Outcomes were: quality of patient-physician end-of-life care communication, prevalence of ACP-discussions 6 months after baseline, symptoms of anxiety and depression in patients and loved ones and quality of death and dying.165 patients were

2019 EvidenceUpdates

118. Glycopyrronium / formoterol fumarate dihydrate (Bevespi Aerosphere) - chronic obstructive pulmonary disease (COPD)

Glycopyrronium / formoterol fumarate dihydrate (Bevespi Aerosphere) - chronic obstructive pulmonary disease (COPD) EMA/752588/2018 EMEA/H/C/004245 Bevespi Aerosphere (glycopyrronium bromide / formoterol) An overview of Bevespi Aerosphere and why it is authorised in the EU What is Bevespi Aerosphere and what is it used for? Bevespi Aerosphere is a medicine used in adults to relieve the symptoms of chronic obstructive pulmonary disease (COPD). COPD is a long-term disease in which the airways (...) only be obtained with a prescription. For more information about using Bevespi Aerosphere, see the package leaflet or contact your doctor or pharmacist. How does Bevespi Aerosphere work? The two active substances in Bevespi Aerosphere work in different ways to widen the airways and improve breathing in COPD. Glycopyrronium bromide is a muscarinic receptor antagonist. This means that it blocks muscarinic receptors (targets) in muscle cells in the lungs. Because these receptors help control

2019 European Medicines Agency - EPARs

119. Capturing Exacerbations of Chronic Obstructive Pulmonary Disease with EXACT. A Subanalysis of FLAME Full Text available with Trip Pro

Capturing Exacerbations of Chronic Obstructive Pulmonary Disease with EXACT. A Subanalysis of FLAME Chronic obstructive pulmonary disease exacerbations accelerate lung function decline, reduce quality of life, and increase mortality. A subset of patients (n = 457) from the FLAME (Effect of Indacaterol Glycopyrronium vs. Fluticasone Salmeterol on COPD Exacerbations) study used the Exacerbations of COPD Tool (EXACT) to capture symptom-defined exacerbations.To evaluate the effect of indacaterol

2019 EvidenceUpdates

120. Fluticasone furoate/umeclidinium/vilanterol (COPD) - Benefit assessment according to §35a Social Code Book V

. The responsibility for the contents of the dossier assessment lies solely with IQWiG. IQWiG employees involved in the dossier assessment: ? Helmut Hörn ? Katharina Hirsch ? Michaela Florina Kerekes ? Ulrike Lampert ? Min Ripoll ? Cornelia Rüdig ? Carolin Weigel ? Beate Wieseler Keywords: fluticasonfuroat, umeclidinium, vilanterol, pulmonary diseasechronic obstructive, benefit assessment, NCT02164513, NCT02345161 Extract of dossier assessment A18-79 Version 1.0 Fluticasone furoate/umeclidinium/vilanterol (COPD (...) by the pharmaceutical company (hereinafter referred to as the “company”). The dossier was sent to IQWiG on 15 November 2018. Research question The aim of this report is to assess the added benefit of FF/UMEC/VI as maintenance therapy compared with the appropriate comparator therapy (ACT) in adults with moderate to severe chronic obstructive pulmonary disease (COPD) who are inadequately controlled with a combination of a long-acting beta-2 sympathomimetic (LABA) and a long-acting muscarinic receptor antagonist (LAMA

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)